PRRT2 and myotonic dystrophy type 1: The PKC inhibitor Ro-31-8220 (Table S2) has previously been shown to reverse CUGBP1 hyperphosphorylation and upregulation, rescuing some of the associated CUGBP1-dependent splicing defects and improving contractile dysfunction and mortality in a heart-specific DM1 mouse model [59].